These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

776 related articles for article (PubMed ID: 34635170)

  • 1. The impact of methamphetamine/amphetamine use on receipt and outcomes of medications for opioid use disorder: a systematic review.
    Frost MC; Lampert H; Tsui JI; Iles-Shih MD; Williams EC
    Addict Sci Clin Pract; 2021 Oct; 16(1):62. PubMed ID: 34635170
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Receipt of Telehealth Services, Receipt and Retention of Medications for Opioid Use Disorder, and Medically Treated Overdose Among Medicare Beneficiaries Before and During the COVID-19 Pandemic.
    Jones CM; Shoff C; Hodges K; Blanco C; Losby JL; Ling SM; Compton WM
    JAMA Psychiatry; 2022 Oct; 79(10):981-992. PubMed ID: 36044198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Methamphetamine use and utilization of medications for opioid use disorder among rural people who use drugs.
    Tsui JI; Whitney BM; Korthuis PT; Chan B; Pho MT; Jenkins WD; Young AM; Cooper HLF; Friedmann PD; Stopka TJ; de Gijsel D; Miller WC; Go VF; Westergaard R; Brown R; Seal DW; Zule WA; Feinberg J; Smith GS; Mixson LS; Fredericksen R; Crane HM; Delaney JA;
    Drug Alcohol Depend; 2023 Sep; 250():110911. PubMed ID: 37549545
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of medications used for opioid use disorder in emergency departments: A cross-sectional analysis of the 2020 National Hospital Ambulatory Medical Care Survey.
    Lee S; Sun L; Vakkalanka JP
    Am J Emerg Med; 2024 Aug; 82():52-56. PubMed ID: 38795424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adherence to and Retention in Medications for Opioid Use Disorder Among Adolescents and Young Adults.
    Viera A; Bromberg DJ; Whittaker S; Refsland BM; Stanojlović M; Nyhan K; Altice FL
    Epidemiol Rev; 2020 Jan; 42(1):41-56. PubMed ID: 32239206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A systematic review of patients' and providers' perspectives of medications for treatment of opioid use disorder.
    Cioe K; Biondi BE; Easly R; Simard A; Zheng X; Springer SA
    J Subst Abuse Treat; 2020 Dec; 119():108146. PubMed ID: 33138929
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Access to Medications for Opioid Use Disorder and Associated Factors Among Adolescents and Young Adults: A Systematic Review.
    Pilarinos A; Bromberg DJ; Karamouzian M
    JAMA Pediatr; 2022 Mar; 176(3):304-311. PubMed ID: 34870707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative Effectiveness Associated With Buprenorphine and Naltrexone in Opioid Use Disorder and Cooccurring Polysubstance Use.
    Xu KY; Mintz CM; Presnall N; Bierut LJ; Grucza RA
    JAMA Netw Open; 2022 May; 5(5):e2211363. PubMed ID: 35536575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pregnancy Rates Among Women Treated with Medication for Opioid Use Disorder.
    Bello JK; Xu KY; Salas J; Bedrick BS; Grucza RA
    J Gen Intern Med; 2024 Jun; 39(8):1342-1348. PubMed ID: 38424347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beliefs about medications for opioid use disorder among Florida criminal problem-solving court & dependency court staff.
    Andraka-Christou B; Atkins D
    Am J Drug Alcohol Abuse; 2020 Nov; 46(6):749-760. PubMed ID: 32969757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treating opioid use disorder in veterans with co-occurring substance use: a qualitative study with buprenorphine providers in primary care, mental health, and pain settings.
    Frost MC; Soyer EM; Achtmeyer CE; Hawkins EJ; Glass JE; Hallgren KA; Williams EC
    Addict Sci Clin Pract; 2023 May; 18(1):26. PubMed ID: 37143162
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of Receipt of Opioid Use Disorder-Related Telehealth Services and Medications for Opioid Use Disorder With Fatal Drug Overdoses Among Medicare Beneficiaries Before and During the COVID-19 Pandemic.
    Jones CM; Shoff C; Blanco C; Losby JL; Ling SM; Compton WM
    JAMA Psychiatry; 2023 May; 80(5):508-514. PubMed ID: 36988913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiac and mortality outcome differences between methadone, buprenorphine and naltrexone prescriptions in patients with an opioid use disorder.
    Wang L; Volkow ND; Berger NA; Davis PB; Kaelber DC; Xu R
    J Clin Psychol; 2023 Dec; 79(12):2869-2883. PubMed ID: 37584532
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparing Reasons for Starting and Stopping Methadone, Buprenorphine, and Naltrexone Treatment Among a Sample of White Individuals With Opioid Use Disorder.
    Randall-Kosich O; Andraka-Christou B; Totaram R; Alamo J; Nadig M
    J Addict Med; 2020; 14(4):e44-e52. PubMed ID: 31651562
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors associated with retention on medications for opioid use disorder among a cohort of adults seeking treatment in the community.
    Biondi BE; Vander Wyk B; Schlossberg EF; Shaw A; Springer SA
    Addict Sci Clin Pract; 2022 Mar; 17(1):15. PubMed ID: 35255967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug use patterns and factors related to the use and discontinuation of medications for opioid use disorder in the age of fentanyl: findings from a mixed-methods study of people who use drugs.
    Hughto JMW; Tapper A; Rapisarda SS; Stopka TJ; Palacios WR; Case P; Silcox J; Moyo P; Green TC
    Subst Abuse Treat Prev Policy; 2023 May; 18(1):30. PubMed ID: 37217975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of COVID-19 and rapid policy exemptions expanding on access to medication for opioid use disorder (MOUD): A nationwide Veterans Health Administration cohort study.
    Livingston NA; Davenport M; Head M; Henke R; LeBeau LS; Gibson TB; Banducci AN; Sarpong A; Jayanthi S; Roth C; Camacho-Cook J; Meng F; Hyde J; Mulvaney-Day N; White M; Chen DC; Stein MD; Weisberg R
    Drug Alcohol Depend; 2022 Dec; 241():109678. PubMed ID: 36368167
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medication for opioid use disorder in the Arab World: A systematic review.
    Alawa J; Muhammad M; Kazemitabar M; Bromberg DJ; Garcia D; Khoshnood K; Ghandour L
    Int J Drug Policy; 2022 Apr; 102():103617. PubMed ID: 35182841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors Associated With the Availability of Medications for Opioid Use Disorder in US Jails.
    Flanagan Balawajder E; Ducharme L; Taylor BG; Lamuda PA; Kolak M; Friedmann PD; Pollack HA; Schneider JA
    JAMA Netw Open; 2024 Sep; 7(9):e2434704. PubMed ID: 39316401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Associations Between Polysubstance Use Patterns and Receipt of Medications for Opioid Use Disorder Among Adults in Treatment for Opioid Use Disorder.
    Ford BR; Bart G; Grahan B; Shearer RD; Winkelman TNA
    J Addict Med; 2021 Apr; 15(2):159-162. PubMed ID: 32868682
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.